Literature DB >> 8557632

Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8.

G B Bolger1, I McPhee, M D Houslay.   

Abstract

In order to characterize the structure and regulation of members of the cAMP-specific phosphodiesterase (PDE) family (Type IV PDEs; PDE4 family), we have cloned from the rat a cDNA, pRPDE39, encoding a novel member of this family, which we call RNPDE4A8. Sequencing of the pRPDE39 cDNA shows it to be encoded by the rat PDE4A gene, but to differ from two other PDE4A transcripts, RD1 (pRPDE8; RNPDE4A1) and pRPDE6 (RNPDE4A5), by the presence of a unique region at its 5' end, consistent with alternative mRNA splicing. The pRPDE39 cDNA encodes a predicted protein of 763 amino acids, of which all but 21, located at the extreme amino terminus, are found in the pRPDE6 protein. Expression of pRPDE39 in COS cells produced a protein of 98 +/- 1.4 kDa, as determined by immunoblotting with an antiserum specific to the carboxyl-terminal regions of all PDE4A proteins, compared to a predicted value of 87.5 kDa. RNase protection analysis detected pRPDE39 mRNA only in testis. Immunoblotting of testis extracts demonstrated two bands of 97 +/- 2 and 87 +/- 3 kDa, the larger of which co-migrated with the band seen in COS cells expressing pRPDE39. COS cell expressed pRPDE39 partitioned between a high speed pellet (particulate) fraction (15% of protein; 8% of activity) and a cytosolic fraction. The particulate fraction had a Km for cAMP of 3.3 +/- 0.6 microM, and the cytosolic fraction a Km of 5.4 +/- 2.8 microM. The Vmax values for the pRPDE39 protein, relative to the RD1 protein, were 0.16 +/- 0.06 and 0.29 +/- 0.05 for the particulate and cytosolic forms, respectively. The pRPDE39-encoded PDE activity could not be removed from the particulate fraction by high salt concentrations, or by nonionic detergents. The pRPDE39-encoded enzyme was inhibited by rolipram at an IC50 of 0.5 +/- 0.2 microM for the particulate form and 1.0 +/- 0.2 microM for the cytosolic form, which are values typical of PDE4 family members. The highly tissue-specific distribution of the pRPDE39 mRNA suggest that the pRPDE39 protein functions to modulate a cAMP signaling pathway that is present largely, if not exclusively, in the testis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557632     DOI: 10.1074/jbc.271.2.1065

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  18 in total

1.  Grueneberg ganglion olfactory subsystem employs a cGMP signaling pathway.

Authors:  Cambrian Y Liu; Scott E Fraser; David S Koos
Journal:  J Comp Neurol       Date:  2009-09-01       Impact factor: 3.215

2.  The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5).

Authors:  J C O'Connell; J F McCallum; I McPhee; J Wakefield; E S Houslay; W Wishart; G Bolger; M Frame; M D Houslay
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

3.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

4.  Phosphodiesterase-4D knock-out and RNA interference-mediated knock-down enhance memory and increase hippocampal neurogenesis via increased cAMP signaling.

Authors:  Yun-Feng Li; Yu-Fang Cheng; Ying Huang; Marco Conti; Steven P Wilson; James M O'Donnell; Han-Ting Zhang
Journal:  J Neurosci       Date:  2011-01-05       Impact factor: 6.167

5.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

6.  Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.

Authors:  G B Bolger; S Erdogan; R E Jones; K Loughney; G Scotland; R Hoffmann; I Wilkinson; C Farrell; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

7.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

8.  Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform.

Authors:  Malcolm Shepherd; Theresa McSorley; Aileen E Olsen; Lee Ann Johnston; Neil C Thomson; George S Baillie; Miles D Houslay; Graeme B Bolger
Journal:  Biochem J       Date:  2003-03-01       Impact factor: 3.857

9.  Human PDE4A8, a novel brain-expressed PDE4 cAMP-specific phosphodiesterase that has undergone rapid evolutionary change.

Authors:  Kirsty F Mackenzie; Emma C Topping; Bozena Bugaj-Gaweda; Chengjun Deng; York-Fong Cheung; Aileen E Olsen; Cecil R Stockard; Lisa High Mitchell; George S Baillie; William E Grizzle; Michael De Vivo; Miles D Houslay; Daguang Wang; Graeme B Bolger
Journal:  Biochem J       Date:  2008-04-15       Impact factor: 3.857

10.  cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors.

Authors:  Graeme B Bolger; Mariana F Bizzi; Sergio V Pinheiro; Giampaolo Trivellin; Lisa Smoot; Mary-Ann Accavitti; Márta Korbonits; Antonio Ribeiro-Oliveira
Journal:  Endocr Relat Cancer       Date:  2016-05       Impact factor: 5.678

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.